Investigators reported a Time x Treatment interaction for MMN peak latency at the FCz electrode. The cohort included nineteen autistic children aged 6–12 years (8 female). Each child received 12 weeks of oral cannabidiol and 12 weeks of placebo in randomised order, with an 8-week washout between periods. EEG was recorded during a duration-deviant auditory oddball task to elicit the automatic auditory deviance signal known as mismatch negativity. The study team observed that latency decreased following CBD exposure but increased following placebo. The uncorrected p-value for that interaction was .029; however, the effect did not remain significant after false discovery rate correction (pFDR = .058). No other latency interactions at Fz or FCz reached significance after correction. These results are limited in scope; they provide preliminary signal only. The authors described the finding as tentative and emphasized the need for replication in larger samples.
The analysis included exploratory correlations between baseline MMN measures and behavioural scores. Data indicated that higher baseline Developmental Behaviour Checklist-2 (DBC-2) Social Relating scores were associated with more negative mean MMN amplitude at both FCz and Fz. Specifically, Spearman rho values were reported at approximately -0.58 (FCz) and -0.59 (Fz), and both associations survived FDR correction (pFDR = .028). The study team noted this association as evidence of a relationship between automatic auditory deviance processing and social-relating difficulties in the sampled autistic children. The analysis was correlational and exploratory; directionality or causality cannot be inferred from these data.
This work is a secondary analysis of a pilot randomised, double-blind, placebo-controlled crossover trial. The primary electrophysiological endpoints for this analysis were mean MMN amplitude and peak latency, evaluated separately at Fz and FCz electrode sites. Nineteen participants completed both treatment arms. Age-adjusted linear mixed-effects models tested Time (baseline, follow-up) x Treatment (CBD, placebo) interactions for amplitude and latency at each electrode. Exploratory Spearman correlations assessed baseline associations between MMN and DBC-2 Social Relating scores. The manuscript reports these methods at a high level. The source did not provide detailed dosing information or specific EEG preprocessing pipelines in the abstract; those methodological details, if present, are in the full manuscript or supplementary material and were not reported in the abstract text used for this summary.
The authors declared no competing interests. The trial is registered (ACTRN12622000437763). Ethical approval was obtained from the Deakin University Human Research Ethics Committee (DUHREC 2020-071), and authors confirmed participant consent and adherence to reporting guidelines. The article is posted as a medRxiv preprint and has not yet been peer reviewed; the authors cautioned that the findings should not be used to guide clinical practice at this stage.
Sample size limits inference. Nineteen participants provided preliminary data but the cohort size constrains power and the precision of effect estimates. The only nominal Time x Treatment effect—reduced latency at FCz after cannabidiol—failed FDR correction and thus should be interpreted with caution. Exploratory correlations between MMN amplitude and DBC-2 Social Relating scores were statistically significant after correction, but these remain observational findings from baseline data. The abstract did not report CBD dosing parameters or full EEG preprocessing and analytic details; those methodological specifics were not included in the abstract and therefore were not available in this summary. The authors recommended larger, adequately powered trials to clarify whether cannabidiol reliably modulates MMN measures in autistic children and to further investigate the link between MMN amplitude and social-relating difficulties. Future work should also report complete dosing regimens, safety outcomes, and pre-specified electrophysiological analysis pipelines so that clinical researchers can evaluate reproducibility and potential clinical relevance.